In this study we explore the roles of the delta isoform of PKC (PKC ) in the regulation of eNOS activity in pulmonary arterial endothelial cells isolated from fetal lambs (FPAECs). Pharmacologic inhibition of PKC with either rottlerin or with the peptide, V1-1 acutely attenuated NO production and this was associated with a decrease in phosphorylation of eNOS at Serine 1177 (S1177). The chronic effects of PKC inhibition using either rottlerin or the over-expression of a dominant negative PKC mutant included the down regulation of eNOS gene expression that was manifested by a decrease in both eNOS promoter activity and protein expression after 24 h of treatment. We also found that PKC inhibition blunted Akt activation as observed by a reduction in phosphorylated Akt at position Serine 473 (Ser473). Thus, we conclude that PKC is actively involved in the activation of Akt. To determine the effect of Akt on eNOS signaling, we over-expressed a dominant negative mutant of Akt and determined its effect of NO generation, eNOS expression, and phosphorylation of eNOS at S1177. Our results demonstrated that Akt inhibition was associated with decreased NO production that correlated with reduced phosphorylation of eNOS at S1177, and decreased eNOS promoter activity. We next evaluated the effect of endogenously produced NO on eNOS expression by incubating FPAECs with the eNOS inhibitor, 2-ethyl-2-thiopseudourea (ETU). ETU significantly inhibited NO production, eNOS promoter activity, and eNOS protein levels. Taken together our data indicate involvement of PKC mediated Akt activation and NO generation in maintaining eNOS expression.
ABSTRACT
In this study we explore the roles of the delta isoform of PKC (PKC ) in the regulation of eNOS activity in pulmonary arterial endothelial cells isolated from fetal lambs (FPAECs). Pharmacologic inhibition of PKC with either rottlerin or with the peptide, V1-1 acutely attenuated NO production and this was associated with a decrease in phosphorylation of eNOS at Serine 1177 (S1177). The chronic effects of PKC inhibition using either rottlerin or the over-expression of a dominant negative PKC mutant included the down regulation of eNOS gene expression that was manifested by a decrease in both eNOS promoter activity and protein expression after 24 h of treatment. We also found that PKC inhibition blunted Akt activation as observed by a reduction in phosphorylated Akt at position Serine 473 (Ser473). Thus, we conclude that PKC is actively involved in the activation of Akt. To determine the effect of Akt on eNOS signaling, we over-expressed a dominant negative mutant of Akt and determined its effect of NO generation, eNOS expression, and phosphorylation of eNOS at S1177. Our results demonstrated that Akt inhibition was associated with decreased NO production that correlated with reduced phosphorylation of eNOS at S1177, and decreased eNOS promoter activity. We next evaluated the effect of endogenously produced NO on eNOS expression by incubating FPAECs with the eNOS inhibitor, 2-ethyl-2-thiopseudourea (ETU). ETU significantly inhibited NO production, eNOS promoter activity, and eNOS protein levels. Taken together our data indicate involvement of PKC mediated Akt activation and NO generation in maintaining eNOS expression. 
INTRODUCTION
After birth, with initiation of ventilation of the lungs, pulmonary vascular resistance decreases and pulmonary blood flow increases 8-to 10-fold to match systemic blood flow (8, 13, 19, 39 ). This process is regulated by a complex and incompletely understood interplay between mechanic and metabolic factors (15) . Recent evidence suggests that normal pulmonary vascular tone is regulated by a complex interaction of vasoactive substances produced by the vascular endothelium including nitric oxide (NO) (15, 17, 32, 52) . NO is an endothelium-derived relaxing factor synthesized by the oxidation of Larginine after activation of endothelial NO synthase (eNOS) (42). L-arginine increases pulmonary blood flow in fetal and newborn lambs and augments endothelium-dependent pulmonary vasodilation (12, 21). In addition, inhaled NO decreases pulmonary vascular resistance in fetal lambs and in newborn lambs with pulmonary hypertension (9, 12, 55).
Conversely, inhibition of NO synthesis increases pulmonary vascular resistance in fetal lambs (12, 43). Basal NO production rises 2-fold from late gestation to one week of life and another 1.6-fold from 1 week to 4 weeks of life in intrapulmonary arteries (16) .
Coinciding with this data, eNOS mRNA and protein increase in late gestation then decrease postnatally in rat and sheep lung parenchyma (20, 28, 30) . Taken together, this data strongly suggests that NO activity mediates, in part, the fall in pulmonary vascular resistance during the transitional pulmonary circulation and maintains the normal low postnatal pulmonary vascular resistance. Thus, the regulation of eNOS gene expression likely plays an important role in controlling the successful transition to air breathing life. 
MATERIALS AND METHODS

Cell culture
Primary cultures of ovine fetal pulmonary artery endothelial cells (PAEC) were isolated as described previously (50). Cells were maintained in DMEM containing phenol red supplemented with 10% fetal calf serum (Hyclone, Logan, UT), antibiotics and antimycotics (MediaTech, Herndon, VA) at 37°C in a humidified atmosphere with 5% CO 2 -95% air. Cells were between passages 3 and 10, seeded at 50% confluence, and utilized when fully confluent.
Infection of Endothelial Cells with Adenovirus
Endothelial cells at 90% confluence were incubated with either an adenovirus containing a dominant-negative mutant of Akt, (Vector Biolabs) or GFP using an MOI of 200:1.
Pharmacologic Inhibition of PKC
We utilized two different methodologies to inhibit PKC . We utilized the PKC specific inhibitor, Rottlerin (10µM) as well as the PKC -derived inhibitory peptide V1-1 (1µM) or a control peptide (1µM) conjugated to a Drosophila antennapedia peptide to allow transfer across the cell membrane (obtained from Dr. Daria Mochly-Rosen, Stanford University).
Generation of a plasmid containing a dominant negative mutant of PKC
A cDNA containing amino acids 2-144 of PKC was subcloned into the mammalian expression plasmid pIRES (Clonetech). In addition, a FLAG epitope was introduced at The plasmid was designated, pIRES-DNPKC .
Overexpression of a dominant negative PKC
Pumonary artery endothelial cells were transfected with pIRES-DNPKC using Effectene
Transfection Reagent (Qiagen) according to the manufacturers directions. Overexpression was analyzed by immunoblotting using anti-Flag Tag mAb (GeneTex Inc.).
Western blotting
PAECs from fetal lambs were serum-starved for 16 hours then treated with 10µM Rottlerin or 100µM ETU and then solubilized with a lysis buffer containing 1% Triton X-100, 20mM Tris pH 7.4, 100mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail (Pierce). Insoluble proteins were precipitated by centrifugation at 13,000 rpm for 10 min at 4°C, and the supernatants were boiled in SDS sample buffer, and subjected to SDS-PAGE on 4-12% polyacrylamide gels and transferred to a PVDF membrane. The blots were blocked with 2% BSA in Tris-buffered saline containing 0.1% Tween (TBST Luciferase activity in protein extracts was determined using the Luciferase assay kit (Promega) and a Fluoroskan Ascent FL luminometer (Thermo electron Corporation).
Statistical Analysis
Statistical calculations were performed using the GraphPad Prism V. 4.01
software. The mean ± SD or SEM were calculated for all samples and significance determined by either by the unpaired t-test or one-way ANOVA with Newman-Keuls post-hoc test. A value of P <0.05 was considered significant. 
RESULTS
Acute effect of PKC inhibition on Akt activation and NO generation
FPAECs were exposed to the PKC specific inhibitor, rottlerin (10µM, 30 min), the PKC derived inhibitory peptide, V1-1 (1µM, 2h), or a control peptide (1µM). Cell lysates were then prepared and subjected Western blot analysis to examine effects on the expression and activity of PKC and Akt. Our initial studies indicate that although total PKC levels were unchanged by either rottlerin ( Fig. 1 A & 
there was a significant decrease in the activating (tyrosine 311) phosphorylation of PKC in cells exposed to either rottlerin ( Fig. 1 A & Since Akt is known to be involved in activating eNOS through the phosphorylation at Ser1177 (11, 14, 26) we then determined the acute effect of rottlerin and the V1-1 peptide on eNOS expression, phosphorylation, and NO generation. Our data indicate that, as with Akt, acute inhibition of PKC with rottlerin or V1-1 did not alter total eNOS protein levels ( 
Generation of a PKC dominant negative mutant expression plasmid
A cDNA containing amino acids 2-144 of PKC and a FLAG epitope was subcloned into the mammalian expression plasmid pIRES to generate a PKC dominant negative mutant (pIRES-DNPKC ). Initial studies were carried out to confirm the dominant negative effect. FPAEC were transfected or not with pIRES-DNPKC . After 24h cell extracst were prepared and Western blot anlysi used to confirm expression of the mutant protein ( Fig. 3 A) . In addition, we found that although PKC levels were unchanged by pIRES-DNPKC ( 
Prolonged effect of PKC inhibition on eNOS expression
FPAECs were exposed to rottlerin (10µM) for 24h then analyzed for eNOS protein expression by Western blot analysis. eNOS protein expression was also compared in cells over-expressing a dominant negative PKC mutant, pIRES-DNPKC . Our data indicated that PKC inhibition significantly reduced eNOS protein levels ( 
Effect of Akt inhibtion on eNOS expression and activity
To further elucidate the potential role of the PKC /Akt axis in regulating eNOS expression we utilized an adenoviral construct to over-express a dominant negative mutant of Akt in 
Effect of endogenous NO on eNOS expression
Our data indicated that the inhibition of PKC /Akt signaling leads to decreased NO Initially we confirmed that the eNOS inhibiton using ETU decreased NO generation. We found that NO x levels were significantly decreased after 24 of ETU (100µM) treatment (Fig. 8 A, P<0 .05 vs. Control). Further, the reduction of NO generation caused significant decreases in both eNOS promoter activity (Fig. 8 B, P<0 .05 vs. Control) and eNOS protein levels ( Regulation of eNOS by PKC been extensively investigated by many groups and the issue of eNOS regulation by PKC is somewhat controversial with some studies indicating that PKC activates eNOS (18, 41 ), while others demonstrate that it inhibits eNOS (6, 38, 40). However, most of the studies completed so far have investigated PKC signaling as a whole rather than determining the effects of individual PKC isoforms. However, previous studies have suggested that specific activation of the PKC isoform can increase NO production in endothelial cells and plays a role in regulation of blood flow in vivo (35) .
Similarly, platelet-activating factor stimulates NO release via PKC in epithelial cells (10). Interestingly we found that phosphorylation of eNOS at Thr495 was not affected by PKC inhibition suggesting that PKC signaling through Thr495 may not be involved in basal NO generation or eNOS expression in FPAEC. However, the role of PKC in conditions of eNOS stimulation (such as shear stress) needs to be investigated.
In this study, we present evidence that the basal regulation of eNOS in pulmonary artery endothelial cells isolated from fetal lambs is dependent on an autocrine signaling pathway that is NO-dependent and regulated by PKC dependent phosphorylation, and activation of Akt. We utilized a number of modalities to inhibit PKC : rottlerin, a PKC inhibitory peptide, and the over-expression of a PKC dominant negative mutant protein.
We utilized these multiple modalities since the specificity of pharmacologic agents can always be questioned. Indeed the use of rottlerin as a specific PKC inhibitor is controversial (1, 24, 33, 45, 46) . Thus, we utilized alternative agents to modulate PKC signaling. We have utilized a dominant negative mutant peptide of PKC ( V-1)
developed by Dr. Mochly-Rosen at Stanford (4, 5) . In addition, we generated a dominant negative mutant plasmid in which a FLAG-tagged V1 domain of PKC was cloned into a pIRES vector under the control of the CMV early promoter (pIRES-DNPKC ). We demonstrate that when FPAECs are treated with rottlerin or the PKC derived inhibitory peptide V1-1, there is an acute inhibition of NO generation followed by a subsequent reduction in eNOS protein levels secondary to a decrease in eNOS promoter activity. In accordance with this, we observed reduced NO generation, eNOS protein levels and We have previously identified PKC as one signal transduction molecule involved in regulating eNOS activation by fluid shear stress (51). In this study we found that both eNOS mRNA and eNOS protein were induced by fluid shear stress. However, when PKC activity was attenuated with the specific PKC inhibitor calphostin C, the shear stressinduced increase in eNOS gene expression was attenuated. When other PKC inhibitors were used (staurosporine, H-7, and bisindolylmaleimide), similar results were obtained.
Together our data implicated PKC in the transduction of the shear stress signal transduction pathway responsible for increased eNOS gene expression. This was further corroborated by the fact that the exposure of FPAECs to the PKC activator phorbol 12-myristate 13-acetate (PMA) lead to an increase in eNOS mRNA levels. However, our data also demonstrated that PKC inhibition alone could lead to a decrease in eNOS mRNA expression (51) suggesting that PKC signaling is required to maintain basal eNOS expression. Thus, the data presented here expand of our earlier study and identify PKC signaling as being a key component in maintaining basal eNOS expression.
Rather than being a constitutive enzyme as was first suggested, eNOS is dynamically regulated at both the transcriptional, post-transcriptional, and post-translational levels.
Protein kinases, other than PKC, have been shown to regulate eNOS activity through phosphorylation at multiple sites. Because several consensus sites for phosphorylation by protein kinases such as PKA, PKB (Akt), and CaM kinase II are found on eNOS, the key role of these kinases in the regulation of NOS through phosphorylation at specific site of that c-Jun plays a key role regulating eNOS expression both through development and by increased flow (51). Thus, we speculate that perhaps NO regulates eNOS transcriptional activity through its ability to increase Sp-1 and/or AP-1 binding activity. However, further studies will be required, using mutant eNOS promoter fragments, to validate this possibility.
In a previous study we investigated the effects of the NO donor sodium nitroprusside (SNP) in cultured ovine FPAECs. SNP was found to be a potent inhibitor of eNOS activity and could reduce eNOS activity in these cells to a significant level within 2 hours of treatment (44). A 24h treatment with SNP did not alter eNOS mRNA and protein levels. Thus, our results demonstrated that NO acts to reduce the catalytic activity of the eNOS protein without altering the transcription or translation of the eNOS gene. However, a previous study from Shaul's group indicated that exogenous NO increased eNOS protein and mRNA levels, resulting in a parallel increase in NOS enzymatic activity in fetal intrapulmonary artery endothelium (54). These two studies were difficult to reconcile.
However, contrary to the effect of exogenous NO observed in our earlier study, we observed that endogenous NO has a positive effect on eNOS activity and abundance such that when FPAECs were treated with eNOS inhibitor ETU, there was significant attenuation of eNOS protein expression and eNOS promoter activity. Further, we found that the addition of SNP prevented the ETU-mediated decrease in eNOS expression. These data imply that endogenous NO has positive feedback effect on eNOS abundance and activity. Thus, our data now suggest the reason for the apparent opposite effects of the two prior studies. The FPAECs used in our studies appear to be capable of producing the 
